Cancer Metastasis & Tumour Markers

Foundations and mechanisms

Definitions and biological significance

Metastasis is the discontinuous spread of malignant cells from a primary tumor to distant sites, where they establish secondary tumors. It is the most important feature distinguishing malignant from benign neoplasms and is responsible for most cancer-related mortality. A tumor becomes clinically dangerous not only by local invasion but also by acquiring the capacity for invasion, survival in circulation, tissue colonization, and growth at a new site.

Tumor markers are measurable molecules produced either by tumor cells or by host tissues in response to tumor. They may be proteins, glycoproteins, hormones, enzymes, oncofetal antigens, or genetic alterations. For USMLE Step 1, the key principle is that most tumor markers are not sufficiently sensitive or specific for general population screening; they are most useful for diagnosis in selected contexts, prognosis, monitoring therapy, and detecting recurrence.

Metastatic cascade: stepwise pathophysiology

1. Clonal expansion and genetic instability: malignant cells accumulate driver mutations affecting proto-oncogenes, tumor suppressor genes, DNA repair genes, and apoptosis regulators. Genomic instability increases heterogeneity, allowing subclones with invasive and metastatic potential to emerge.
2. Loss of cell adhesion: many carcinomas reduce expression or function of E-cadherin, a calcium-dependent epithelial adhesion molecule. Loss of E-cadherin facilitates detachment from neighboring cells and is classically associated with diffuse-type gastric carcinoma and invasive lobular breast carcinoma.
3. Local invasion of extracellular matrix: tumor cells attach to matrix proteins such as laminin and fibronectin, then degrade basement membrane and interstitial matrix using proteases, especially matrix metalloproteinases. Type IV collagenase is important because basement membranes contain type IV collagen.
4. Epithelial-to-mesenchymal transition: epithelial tumor cells may acquire a motile, spindle-shaped phenotype with decreased cytokeratin/E-cadherin and increased vimentin, promoted by transcription factors such as SNAIL, SLUG, and TWIST.
5. Angiogenesis: tumors generally cannot grow beyond approximately 1–2 mm in diameter without neovascularization because diffusion of oxygen and nutrients becomes inadequate. Hypoxia stabilizes HIF-1α, increasing VEGF expression. New tumor vessels are tortuous and leaky, facilitating intravasation.
6. Intravasation and survival in blood: circulating tumor cells must resist shear stress and immune killing. They often form aggregates with platelets, which shield them from natural killer cells and assist endothelial adhesion.
7. Extravasation and colonization: tumor cells adhere to distant endothelium, exit vessels, and adapt to the local microenvironment. Successful macrometastasis requires growth, angiogenesis, and evasion of local immune defenses.

Routes and patterns of spread

Route	Typical tumors	High-yield pattern
Lymphatic spread	Carcinomas	Initial spread to regional lymph nodes; sentinel node concept reflects first draining lymph node basin.
Hematogenous spread	Sarcomas; also renal cell carcinoma, hepatocellular carcinoma, follicular thyroid carcinoma, choriocarcinoma	Commonly via veins; liver and lung are frequent targets because they receive portal and systemic venous drainage.
Transcoelomic seeding	Ovarian carcinoma, gastric carcinoma, appendiceal mucinous tumors	Spread across peritoneal, pleural, pericardial, or subarachnoid spaces; ovarian carcinoma classically seeds peritoneum and omentum.
Perineural invasion	Pancreatic adenocarcinoma, prostate carcinoma, head and neck cancers	Local spread along nerves; associated with pain and recurrence risk.

The “seed and soil” hypothesis explains organ tropism: metastatic cells (“seeds”) grow preferentially in permissive microenvironments (“soil”). Examples include prostate carcinoma metastasizing to bone, colon carcinoma to liver via portal drainage, and lung carcinoma to adrenal glands and brain.

Staging, grading, and metastatic classification

Grade describes microscopic differentiation and proliferative activity: well-differentiated tumors resemble tissue of origin, whereas poorly differentiated or anaplastic tumors show pleomorphism, hyperchromasia, abnormal mitoses, and loss of architecture. Stage describes anatomic extent and is usually more prognostically important than grade.

TNM component	Meaning	Core concept
T	Primary tumor size or local invasion	Tis denotes carcinoma in situ; increasing T category reflects larger size or deeper invasion.
N	Regional lymph node involvement	N0 means no regional nodes; N1–N3 indicate increasing nodal burden or location.
M	Distant metastasis	M0 means absent; M1 means distant metastasis and often defines stage IV solid tumor disease.

Core tumor marker principles

A useful tumor marker should ideally have high sensitivity and specificity, correlate with tumor burden, and have predictable kinetics. Marker interpretation requires understanding half-life: after complete tumor removal, the marker should fall according to first-order decay. Failure to decline appropriately suggests residual disease; a later rise suggests recurrence. However, false positives occur with benign inflammation, smoking, pregnancy, liver disease, and renal dysfunction.

Marker	Major association	Key numbers and concepts
AFP	Hepatocellular carcinoma; yolk sac tumor; nonseminomatous germ cell tumor	Adult reference commonly <10 ng/mL; serum half-life approximately 5–7 days; also increased in pregnancy and hepatitis.
β-hCG	Choriocarcinoma; testicular germ cell tumors; hydatidiform mole	Half-life approximately 24–36 hours; may cause hyperthyroidism by weak TSH receptor stimulation.
CEA	Colorectal, pancreatic, gastric, breast carcinomas	Typical upper limit <3 ng/mL in nonsmokers and <5 ng/mL in smokers; best for monitoring colorectal cancer recurrence, not screening.
CA-125	Epithelial ovarian carcinoma	Common cutoff >35 U/mL; elevated in endometriosis, menstruation, pregnancy, cirrhosis, and pelvic inflammation.
CA 19-9	Pancreatic adenocarcinoma; cholangiocarcinoma	Common cutoff >37 U/mL; falsely elevated with biliary obstruction and cholangitis; absent in Lewis antigen-negative individuals.
PSA	Prostate adenocarcinoma and benign prostatic hyperplasia	Traditional abnormal threshold >4 ng/mL; organ-specific but not cancer-specific; free PSA fraction is lower in cancer.

Mechanistically, many markers reflect dedifferentiation or embryologic reprogramming. Oncofetal antigens such as AFP and CEA are normally expressed during fetal development, silenced in adult tissues, and re-expressed in malignant transformation. Step 1 questions often test whether a marker is diagnostic, prognostic, or useful for monitoring; in general, a marker that tracks tumor burden is most useful when interpreted serially rather than as a single isolated value.

Clinical assessment and investigations

Presentation suggesting metastatic cancer

Metastasis is the spread of malignant cells from a primary tumor to noncontiguous sites via lymphatics, blood, transcoelomic seeding, or direct extension. Clinically, metastatic disease may present before the primary tumor is known. Constitutional features include unintentional weight loss, anorexia, fatigue, fever, and night sweats, reflecting cytokine release, cachexia, or high tumor burden. Localizing symptoms often reflect the biology of metastatic routes: lymphatic spread produces firm, fixed, nontender lymphadenopathy; hematogenous spread commonly involves liver, lung, bone, and brain because of vascular drainage patterns and “seed-and-soil” organotropism.

• Lymph nodes: hard, fixed nodes; left supraclavicular node (Virchow node) suggests abdominal malignancy, especially gastric carcinoma.
• Bone: persistent focal pain, pathologic fracture, hypercalcemia; prostate cancer classically causes osteoblastic lesions, whereas renal cell, thyroid, lung, and multiple myeloma often cause lytic lesions.
• Liver: hepatomegaly, right upper quadrant pain, jaundice, elevated alkaline phosphatase; colon cancer often spreads to liver via portal venous drainage.
• Lung: cough, dyspnea, pleural effusion, hemoptysis, multiple “cannonball” nodules on imaging.
• Brain: headache, seizure, focal neurologic deficit; lung, breast, melanoma, renal cell carcinoma, and choriocarcinoma are classic primaries.
• Peritoneum: ascites, bowel obstruction, omental caking; ovarian and gastrointestinal cancers are common causes.

Differential diagnosis

Metastatic malignancy must be distinguished from benign, inflammatory, infectious, and hematologic processes. The differential is guided by distribution, tempo, systemic symptoms, and tissue diagnosis.

Finding	Important differentials	Clues favoring malignancy
Generalized lymphadenopathy	Viral infection, tuberculosis, HIV, sarcoidosis, lymphoma, metastatic carcinoma	Hard fixed nodes, B symptoms, supraclavicular location, abnormal CBC
Liver lesions	Hemangioma, abscess, cysts, focal nodular hyperplasia, hepatocellular carcinoma, metastases	Multiple lesions, known primary tumor, high alkaline phosphatase, weight loss
Bone pain/lesions	Trauma, osteomyelitis, Paget disease, hyperparathyroidism, myeloma, metastases	Night pain, pathologic fracture, hypercalcemia, elevated PSA or alkaline phosphatase
Ascites/peritoneal disease	Cirrhosis, heart failure, nephrotic syndrome, tuberculosis, ovarian/GI malignancy	SAAG <1.1 g/dL, high protein, malignant cells on cytology

Investigations and staging principles

Tissue diagnosis is the gold standard. Imaging may strongly suggest malignancy, but histology confirms invasion, tumor type, grade, and biomarker profile. Biopsy options include fine-needle aspiration, core needle biopsy, excisional biopsy, or image-guided biopsy of the most accessible lesion. Immunohistochemistry is high-yield for identifying tumor lineage: cytokeratin suggests carcinoma, CD45 lymphoma, S100/SOX10 melanoma, desmin muscle differentiation, TTF-1 lung adenocarcinoma or thyroid carcinoma, PSA prostatic origin, and PAX8 renal, thyroid, or Müllerian origin.

Initial laboratory evaluation often includes CBC, electrolytes, calcium, creatinine, liver enzymes, alkaline phosphatase, bilirubin, albumin, LDH, and urinalysis. Hypercalcemia may result from PTHrP secretion, osteolytic metastases, or calcitriol production. Elevated alkaline phosphatase suggests cholestasis or osteoblastic bone activity. LDH is a nonspecific marker of high cell turnover and adverse prognosis in lymphoma, melanoma, germ cell tumors, and many advanced cancers.

Staging commonly uses the TNM system: T describes primary tumor size/local invasion, N regional nodal involvement, and M distant metastasis. In most solid tumors, M1 disease equals stage IV. Sentinel lymph node biopsy assesses the first draining node basin, particularly in breast cancer and melanoma; a negative sentinel node reduces the likelihood of regional nodal spread but does not exclude hematogenous micrometastasis.

• CT chest/abdomen/pelvis: standard anatomic staging for many solid tumors.
• MRI: superior soft-tissue contrast; preferred for brain, spinal cord compression, liver lesion characterization, and pelvic tumors.
• Bone scan: technetium-99m detects osteoblastic activity; sensitive for prostate and breast metastases but less sensitive for purely lytic lesions.
• FDG-PET: uses fluorodeoxyglucose uptake by metabolically active cells; false positives occur with infection/inflammation and false negatives with low-grade or mucinous tumors.

Tumor markers: interpretation and thresholds

Tumor markers are molecules produced by tumor cells or host tissues. They are most useful for monitoring treatment response, detecting recurrence, risk stratification, or supporting a diagnosis; they are rarely sufficiently sensitive and specific for population screening. A marker’s positive predictive value depends strongly on disease prevalence, so false positives are common in low-risk populations.

Marker	Classic associations	Approximate reference/threshold	High-yield interpretation
AFP	Hepatocellular carcinoma, yolk sac tumor, nonseminomatous germ cell tumor	Usually <10 ng/mL; AFP >400 ng/mL strongly supports HCC in appropriate context	Half-life about 5–7 days; also elevated in pregnancy, hepatitis, cirrhosis
β-hCG	Choriocarcinoma, testicular germ cell tumors, hydatidiform mole	Nonpregnant usually <5 mIU/mL	Half-life about 24–36 hours; may cause gynecomastia or hyperthyroidism via TSH receptor cross-reactivity
PSA	Prostate adenocarcinoma, benign prostatic hyperplasia, prostatitis	Traditional concern >4 ng/mL	Not cancer-specific; lower free PSA fraction increases concern for malignancy
CA-125	Epithelial ovarian carcinoma	Often abnormal >35 U/mL	Elevated in endometriosis, menstruation, pregnancy, peritonitis; useful for monitoring recurrence
CA 19-9	Pancreatic adenocarcinoma, cholangiocarcinoma	Often abnormal >37 U/mL	Can rise with cholestasis; Lewis antigen-negative individuals may not produce it
CEA	Colorectal, pancreatic, gastric, breast cancers	Usually <3 ng/mL in nonsmokers; may be <5 ng/mL in smokers	Best used for colorectal cancer recurrence monitoring, not screening
Calcitonin	Medullary thyroid carcinoma	Assay-dependent; elevated above reference range is abnormal	Derived from parafollicular C cells; MEN2 association
Thyroglobulin	Differentiated thyroid carcinoma follow-up	Should be very low/undetectable after total thyroidectomy and ablation	Anti-thyroglobulin antibodies can falsely alter results

Serial trends are usually more informative than a single value and should be interpreted using the same assay when possible. A falling marker after resection or chemotherapy suggests reduced tumor burden if the decline matches the marker half-life; failure to normalize suggests residual disease, metastatic disease, or an incorrect diagnosis.

Management, pharmacology and procedures

General principles: treating metastatic disease

Metastasis usually defines stage IV disease in TNM staging (M1), except for certain hematologic malignancies and some tumors with regional spread patterns. Management is based on tumor histology, anatomic extent, performance status, and molecular drivers. For USMLE Step 1, the key concept is that local therapy treats anatomically confined disease, whereas systemic therapy is required when malignant cells have disseminated through blood, lymphatics, or serosal cavities.

• Surgery: potentially curative for localized tumors; may be palliative in metastasis, e.g., bowel obstruction, bleeding, or solitary “oligometastatic” lesions.
• Radiation therapy: ionizing radiation causes DNA double-strand breaks via free radicals; oxygen enhances radiosensitivity. Used for local control, painful bone metastases, brain metastases, and spinal cord compression.
• Systemic therapy: chemotherapy, endocrine therapy, targeted therapy, or immunotherapy; choice depends on tumor biology rather than anatomic site alone.
• Palliation and survivorship: symptom control, nutrition, pain management, thromboembolism prevention, and monitoring for recurrence or treatment toxicity.

Acute complications of metastasis

Emergency	Mechanism	Key management
Spinal cord compression	Vertebral metastasis compresses cord; classically breast, lung, prostate, kidney, thyroid	MRI spine; dexamethasone 10 mg IV load, then 4–6 mg IV/PO every 6 h; urgent radiation or decompressive surgery
Hypercalcemia of malignancy	PTHrP secretion, osteolytic metastases, or vitamin D production	Normal Ca2+ ≈ 8.5–10.5 mg/dL; treat severe/symptomatic disease with IV normal saline, calcitonin 4 IU/kg SC/IM q12h, plus zoledronic acid 4 mg IV over ≥15 min or denosumab
Brain metastases with edema	Blood-brain barrier disruption causes vasogenic edema	Dexamethasone reduces capillary permeability; stereotactic radiosurgery or whole-brain radiation depending on burden; anticonvulsants only if seizures occur
Malignant effusion	Pleural/peritoneal seeding obstructs lymphatic drainage	Diagnostic/therapeutic thoracentesis or paracentesis; cytology; recurrent pleural effusions may require indwelling catheter or pleurodesis

High-yield anticancer pharmacology

Cytotoxic drugs preferentially injure rapidly dividing cells, explaining common toxicities: myelosuppression, mucositis, alopecia, infertility, and secondary malignancy. Targeted and immune therapies exploit oncogenic signaling or antitumor immunity.

Class	Mechanism	Classic toxicity/association
Alkylators, e.g., cyclophosphamide	Covalently cross-link DNA	Hemorrhagic cystitis from acrolein; prevented with mesna
Platinum drugs, e.g., cisplatin	DNA cross-linking	Nephrotoxicity, ototoxicity, peripheral neuropathy
Antimetabolites, e.g., methotrexate, 5-FU	Inhibit nucleotide synthesis; S-phase specific	Methotrexate inhibits DHFR; leucovorin rescue; 5-FU inhibits thymidylate synthase
Microtubule inhibitors	Vinca alkaloids inhibit polymerization; taxanes inhibit depolymerization	Vincristine neuropathy; paclitaxel hypersensitivity and neuropathy
HER2, EGFR, BCR-ABL inhibitors	Block oncogenic receptor or kinase signaling	Trastuzumab: cardiomyopathy; imatinib: BCR-ABL, c-KIT, PDGFR inhibition
Immune checkpoint inhibitors	Anti-CTLA-4, anti-PD-1, or anti-PD-L1 increase T-cell activity	Autoimmune-like colitis, dermatitis, hepatitis, endocrinopathies

Procedures, staging, and monitoring

Diagnosis of metastasis generally requires tissue confirmation. A biopsy of the primary tumor or accessible metastatic lesion provides histology, immunohistochemistry, and molecular testing. Sentinel lymph node biopsy, commonly used in breast cancer and melanoma, maps first-draining nodes using technetium-99m radiotracer and/or blue dye. Nodal deposits are classified as isolated tumor cells <0.2 mm, micrometastases 0.2–2 mm, and macrometastases >2 mm.

Response to therapy is often measured radiographically using RECIST: partial response is at least a 30% decrease in the sum of target lesion diameters; progressive disease is at least a 20% increase plus ≥5 mm absolute growth or any new lesion.

Marker	Normal/threshold	Major uses and caveats
AFP	Adult usually <10 ng/mL; half-life 5–7 days	Hepatocellular carcinoma, yolk sac tumor; also elevated in pregnancy and liver injury
β-hCG	Nonpregnant <5 mIU/mL; half-life 24–36 h	Gestational trophoblastic disease, choriocarcinoma, testicular germ cell tumors
CEA	Nonsmoker <3 ng/mL; smoker <5 ng/mL	Colorectal cancer surveillance; not specific enough for screening
CA-125	<35 U/mL	Epithelial ovarian cancer monitoring; elevated in endometriosis, menstruation, pregnancy, cirrhosis
PSA	Often abnormal if >4 ng/mL; half-life 2–3 days	Prostate cancer monitoring; after prostatectomy should become undetectable; biochemical recurrence often PSA ≥0.2 ng/mL confirmed

Tumor markers are best used for baseline risk stratification, treatment response, and recurrence surveillance, not as stand-alone screening tests. Serial values should be interpreted with the same assay and in relation to marker half-life, tumor burden, renal/hepatic clearance, and benign causes of elevation.

Exam controversies and advanced synthesis

Screening, surveillance, and the tumour-marker fallacy

High-yield principle: most tumour markers are better for monitoring known disease than for screening asymptomatic populations. A marker with imperfect specificity produces many false positives when disease prevalence is low; therefore, positive predictive value depends strongly on pretest probability. Step 1 questions often test this statistical pitfall rather than asking for clinical algorithms.

Marker	Typical normal value	Half-life	High-yield use	Common pitfall
AFP	<10 ng/mL in adults	5–7 days	Hepatocellular carcinoma; yolk sac tumour; nonseminomatous germ cell tumours	Can rise in hepatitis, cirrhosis, pregnancy; pure seminoma should not elevate AFP
β-hCG	<5 mIU/mL in nonpregnant adults	24–36 hours	Choriocarcinoma; testicular germ cell tumours; pregnancy-related disease	May cause gynecomastia via LH receptor stimulation
CEA	<3 ng/mL nonsmokers; <5 ng/mL smokers	3–5 days	Colorectal cancer recurrence surveillance	Poor screening test; increased by smoking, pancreatitis, IBD, cirrhosis
CA-125	<35 U/mL	Approximately 5 days	Epithelial ovarian cancer monitoring	Elevated in endometriosis, menstruation, pregnancy, PID, peritonitis
PSA	Often <4 ng/mL, age-dependent	2–3 days	Prostate cancer detection and recurrence monitoring	Elevated in BPH, prostatitis, ejaculation, manipulation; overdiagnosis controversy

Guidelines and landmark controversies relevant to Step 1

PSA screening is the classic controversy. The USPSTF recommends individualized shared decision-making for men aged 55–69 years and recommends against routine PSA screening at age ≥70 years. The European ERSPC trial showed an approximate 20% relative reduction in prostate cancer mortality but substantial overdiagnosis; the US PLCO trial showed no clear mortality benefit, partly due to contamination from screening in the control group. For Step 1, the key lesson is that screening can increase diagnosis without proportionally decreasing mortality, because of lead-time bias, length-time bias, and detection of indolent tumours.

CA-125 is not recommended for average-risk ovarian cancer screening. Large trials including PLCO and UKCTOCS did not demonstrate a convincing all-cause mortality benefit. CA-125 is most useful when interpreted longitudinally in a patient with known epithelial ovarian carcinoma. Likewise, CEA should not be used to screen for colon cancer; colonoscopy-based strategies detect premalignant adenomas, whereas serum CEA lacks sensitivity and specificity.

AFP for hepatocellular carcinoma is nuanced. Many liver societies support ultrasound surveillance every 6 months in high-risk patients such as cirrhosis or chronic hepatitis B; AFP may be added, but is neither perfectly sensitive nor specific. A commonly tested AFP threshold is around 20 ng/mL, with only moderate sensitivity. Very high AFP values, particularly hundreds to thousands of ng/mL, are more concerning but still require anatomic correlation.

Metastatic biology: integrating route, organ tropism, and staging

Metastasis requires sequential acquisition of biologic capabilities: loss of adhesion, basement membrane invasion, intravasation, survival in circulation, extravasation, and colonization. Important mediators include reduced E-cadherin, matrix metalloproteinases, epithelial-to-mesenchymal transition, angiogenesis via VEGF, and immune evasion. However, metastasis is not merely mechanical embolization. Paget’s “seed and soil” hypothesis explains organ tropism: tumour cells preferentially colonize microenvironments that provide compatible growth signals.

• Carcinomas commonly spread first via lymphatics; sarcomas more often spread hematogenously, but exceptions are common.
• Colon cancer commonly metastasizes to liver via the portal circulation.
• Lung cancer commonly metastasizes to brain, bone, adrenal glands, and liver.
• Prostate cancer classically causes osteoblastic bone metastases; breast cancer often causes lytic or mixed bone lesions.
• Krukenberg tumour denotes metastatic mucin-producing signet-ring carcinoma to the ovary, classically from stomach.

In TNM staging, T reflects primary tumour extent, N regional lymph node involvement, and M distant metastasis. In many solid tumours, M1 disease defines stage IV, but prognosis varies dramatically by tumour type. This is why Step 1 separates stage from grade: stage is anatomic spread; grade is histologic differentiation and proliferative aggressiveness. A small high-grade tumour may be biologically dangerous, whereas a low-grade tumour with distant spread is advanced by stage.

Viva-level pitfalls and synthesis points

• Do not equate marker elevation with cancer. Inflammation, pregnancy, smoking, liver disease, and benign hyperplasia can raise markers.
• Do not equate normal markers with absence of cancer. Some tumours are nonsecretory or poorly differentiated and lose marker production.
• Marker kinetics matter. After resection or chemotherapy, persistent elevation beyond expected half-lives suggests residual disease, recurrence, or metastasis.
• Pure seminoma does not produce AFP. Elevated AFP in a testicular mass implies a nonseminomatous component even if histology samples seminoma-like tissue.
• Sentinel lymph node is the first draining node of a tumour basin; positivity indicates metastatic access to lymphatics and guides staging, especially in breast cancer and melanoma.
• Virchow node is left supraclavicular lymphadenopathy from thoracic duct drainage; Sister Mary Joseph nodule is umbilical metastasis from intra-abdominal or pelvic malignancy.

The exam-level synthesis is that tumour markers, metastatic route, histology, and staging are complementary data streams. A correct answer usually requires matching mechanism to pattern: epithelial malignancy invading lymphatics, portal drainage to liver, osteoblastic prostate metastases, AFP/β-hCG kinetics in germ cell tumours, or PSA/CA-125 controversies arising from false positives and overdiagnosis.